Apimeds Pharmaceuticals US, Inc. Common Stock (APUS)

MindWave Innovations (NYSE American: APUS) is a digital asset and technology company providing institutional-grade treasury infrastructure for the digital asset economy. The company offers a secure and compliant gateway to digital assets through insured custody solutions, AI-enabled yield strategies, and transparent reporting systems. MindWave is focused on supporting corporations and institutional counterparties in holding, managing, and generating risk-aware yield on Bitcoin reserves through a disciplined, technology-driven platform.

MindWave Innovations (NYSE American: APUS) is a digital asset and technology company providing institutional-grade treasury infrastructure for the digital asset economy. The company offers a secure and compliant gateway to digital assets through insured custody solutions, AI-enabled yield strategies, and transparent reporting systems. MindWave is focused on supporting corporations and institutional counterparties in holding, managing, and generating risk-aware yield on Bitcoin reserves through a disciplined, technology-driven platform.

Rejects Allegations of MindWave Innovations, Inc.

MindWave Innovations Inc., a Delaware corporation and wholly owned subsidiary of Apimeds Pharmaceuticals US, Inc. (“APUS” or the “Company”) (NYSE American: APUS), today announced that on March 20, 2026, Inscobee Inc. (KS:006490) and its wholly owned subsidiary Apimeds Inc. (together, “Inscobee”), in concert with certain other stockholders, filed an Amendment No. 2 to Schedule 13D with the Securities and Exchange Commission purporting to effect a hostile takeover of the Company’s Board of Directors by written consent.

Apimeds Pharmaceuticals US, Inc. and Lōkahi Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) Division of Anesthesiology, Addiction Medicine and Pain Medicine (DAAP) has confirmed a Type C meeting to discuss LT-100 (Apitox), a non-opioid biologic candidate being developed for the treatment of the signs and symptoms of osteoarthritis (OA). The meeting will be conducted via teleconference on Monday, May 4, 2026.

Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) today announced the closing of its previously announced $100 million private investment in public equity (PIPE) financing. This substantial investment reinforces the Company’s financial position and propels its late-stage non-opioid therapeutic programs toward key clinical and regulatory milestones.

(NYSE American: APUS) Apimeds Pharmaceuticals US, Inc. (“Apimeds”), a clinical-stage biotechnology company that completed its IPO in May 2025, today announced that it has merged with MindWave Innovations Inc (“MindWave”; the transaction, the “Merger”). Today, Apimeds and MindWave signed the merger agreement (the “Merger Agreement”) outlining the terms of the Merger, thus paving the way for a dual-growth enterprise spanning advanced biotechnology and institutional digital-asset treasury solutions.

Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds”) today announced the expansion of its ai² Futures Lab™ program through a new collaboration with the University of Idaho College of Business and Economics, beginning in the Spring 2026 semester. The initiative connects student teams with real-world biopharma business development projects, reinforcing Apimeds’ commitment to fostering innovation, leadership, and discovery across the healthcare ecosystem.

Apimeds Pharmaceuticals US, Inc. (NYSE: APUS) (“Apimeds”) today announced the expansion of the Apimeds ai² Futures Lab program through a new collaboration with the University of Oregon’s Lundquist College of Business, starting with the Winter 2026 quarter. The initiative connects student teams with real-world biopharma business development projects, reinforcing Apimeds’ commitment to fostering innovation, leadership, and discovery across the healthcare ecosystem.

Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds”) today announced the expansion of its ai² Future Labs program by engaging graduate students from the University of San Diego’s Knauss School of Business. The initiative is designed to identify promising pharmaceutical assets critical to improving human health while cultivating the next generation of business leaders for the biopharmaceutical industry.

Apimeds Pharmaceuticals US, Inc. (NYSE: APUS) today welcomed the U.S. Food and Drug Administration’s (FDA) newly released draft guidance on the development of non-opioid pain therapies, highlighting its potential to accelerate the company’s lead program, Apitox, for chronic osteoarthritis pain. The draft guidance, entitled “Development of Non-Opioid Analgesics for Chronic Pain, Draft Guidance for Industry”, can be found here: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-non-opioid-analgesics-chronic-pain.

Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds”) today announced the launch of its ai² Future Labs program in partnership with The University of Alabama Culverhouse College of Business’s STEM Path to the MBA program. The initiative aims to identify important assets critical to improving human health and to cultivate the next generation of pharmaceutical industry business leaders.

Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.

Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), a clinical-stage biopharmaceutical company developing Apitox, an intradermally administered, bee venom-based therapeutic, today announced two key additions to its executive leadership team. Susan Kramer, DrPH, has been appointed Senior Vice President of Development, and Brian Peters has joined as Head of the Company’s proprietary ai²™ division.